^
Association details:
| Biomarker: | FGFR2 rearrangement |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | tinengotinib (TT-00420) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis.
Published date:
01/17/2023
Excerpt:
Eligible patients (pts) with advanced/metastatic CCA exhausting standard treatment options received tinengotinib 10 mg QD….Overall DCR (CR or PR+SD) was 90% (9/10) in FGFR2 fusion/rearrangement pts; 100% in FGFR primary mutation pt (1/1)....The preliminary biomarker analysis suggests loss of resistant FGFR mutation on liquid biopsy post tinengotinib therapy....Tinengotinib may result in promising clinical benefit for CCA pts in the setting of FGFRi-resistance.
DOI:
10.1200/JCO.2023.41.3_suppl.539
Trial ID:
